Simone Belmonti

Efficacy and tolerability of lamivudine plus dolutegravir compared with lamivudine plus boosted PIs in HIV-1 positive individuals with virologic suppression: a retrospective study from the clinical practice

Alberto Borghetti, Francesca Lombardi, Roberta Gagliardini et al. · BMC Infectious Diseases · 2019 · 32 citations · Full text

Evolution of blood-associated HIV-1 DNA levels after 48 weeks of switching to atazanavir/ritonavir+lamivudine dual therapy versus continuing triple therapy in the randomized AtLaS-M trial

Francesca Lombardi, Simone Belmonti, Eugenia Quirós-Roldán et al. · Journal of Antimicrobial Chemotherapy · 2017 · 31 citations · Full text

<i>SLC22A2</i> variants and dolutegravir levels correlate with psychiatric symptoms in persons with HIV

Alberto Borghetti, Andrea Calcagno, Francesca Lombardi et al. · Journal of Antimicrobial Chemotherapy · 2018 · 29 citations · Full text

Immunogenicity and Safety of the 13-Valent Pneumococcal Conjugate Vaccine versus the 23-Valent Polysaccharide Vaccine in Unvaccinated HIV-Infected Adults: A Pilot, Prospective Controlled Study

Francesca Lombardi, Simone Belmonti, Massimiliano Fabbiani et al. · PLoS ONE · 2016 · 28 citations · Full text

Systemic inflammation markers after simplification to atazanavir/ritonavir plus lamivudine in virologically suppressed HIV-1-infected patients: ATLAS-M substudy

Simone Belmonti, Francesca Lombardi, Eugenia Quirós-Roldán et al. · Journal of Antimicrobial Chemotherapy · 2018 · 19 citations · Full text